A PYMNTS Company

FTC proposes order settling charges related to Novartis-Fougera merger

By  |  July 16, 2012

The Federal Trade Commission has announced a proposed order settling charges against Novartis for its $1.5 billion acquisition of Fougera. The original deal, according to the FTC, would violate Section 5 of the FTC Act and Section 7 of the Clayton Act because it eliminates a significant competitor in each market for four topical drugs.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The proposed order calls for Novartis giving up its marketing rights to generic calcipotriene topical solution, generic lidocaine-prilocaine cream, generic metronidazole topical gel, and diclofenac sodium gel. The drugs are used to treat conditions such as psoriasis, rosacea, and pain from injections and surgery. Marketing rights to the drugs will be returned to Tolmar, the developer and manufacturer of the drugs.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Full content: FTC Press Release

     

    Related content: Closed but Not Forgotten: Government Review of Consummated Mergers Under Section 7 of the Clayton Act

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.